Search research articles
Contact Us
Filters
Showing results (131-140 of 186) with videos related to
Page
of 19
Sort By:
Cancer Discovery
|
June 13, 2024
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group
Elliot Stieglitz, Alex G Lee, Steven P Angus, et al.
Pediatric Blood & Cancer
|
December 19, 2013
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621)
Elizabeth Fox, Yael P Mosse', Holly M Meany, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 18, 2006
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors
Elizabeth Fox, John M Maris, Brigitte C Widemann, et al.
Cancer
|
September 11, 2020
ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study
James I Geller, Joseph G Pressey, Malcolm A Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 21, 2019
Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)
Kristina A Cole, Sharmistha Pal, Rachel A Kudgus, et al.
Neuro-Oncology
|
February 11, 2004
Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium
Ramsis K Benjamin, Fred H Hochberg, Elizabeth Fox, et al.
Pediatric Blood & Cancer
|
November 15, 2019
Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)
Eric S Schafer, Rachel E Rau, Stacey L Berg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 9, 2024
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric <i>NTRK</i> Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823)
Theodore W Laetsch, Stephan Voss, Kathleen Ludwig, et al.
Pediatric Blood & Cancer
|
August 12, 2021
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors
Holly J Meany, Brigitte C Widemann, Pamela S Hinds, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2019
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)
Yael P Mossé, Elizabeth Fox, David T Teachey, et al.
Page
of 19
Search research articles
Search
Showing results (131-140 of 186) with videos related to
Sort By:
Page
of 19
Cancer Discovery
|
June 13, 2024
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group
Elliot Stieglitz, Alex G Lee, Steven P Angus, et al.
Pediatric Blood & Cancer
|
December 19, 2013
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621)
Elizabeth Fox, Yael P Mosse', Holly M Meany, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 18, 2006
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors
Elizabeth Fox, John M Maris, Brigitte C Widemann, et al.
Cancer
|
September 11, 2020
ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study
James I Geller, Joseph G Pressey, Malcolm A Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 21, 2019
Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)
Kristina A Cole, Sharmistha Pal, Rachel A Kudgus, et al.
Neuro-Oncology
|
February 11, 2004
Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium
Ramsis K Benjamin, Fred H Hochberg, Elizabeth Fox, et al.
Pediatric Blood & Cancer
|
November 15, 2019
Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)
Eric S Schafer, Rachel E Rau, Stacey L Berg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 9, 2024
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric <i>NTRK</i> Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823)
Theodore W Laetsch, Stephan Voss, Kathleen Ludwig, et al.
Pediatric Blood & Cancer
|
August 12, 2021
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors
Holly J Meany, Brigitte C Widemann, Pamela S Hinds, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2019
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)
Yael P Mossé, Elizabeth Fox, David T Teachey, et al.
Page
of 19